



25 June 2026
EMA/127631/2026
Press Office

Start of union reviews

CHMP meeting of 22-25 June 2026

Table 1. Start of reviews for non-centrally authorised medicines

Name	INN	Type of procedure	Scope
Rifadin oral suspension and syrup and associated names	rifampicin	Article 31 of Directive 2001/83/EC	Procedure triggered by the Netherlands asking for an opinion on the impact of the possible carcinogenic risk posed by the excipient diethanolamine (DEA) on the benefit-risk balance of Rifadin oral suspension and syrup and associated names in its authorised indications, and on possible options to replace DEA in these medicinal products.

